Contribute Try STAT+ Today

immunotherapy

Most Read

Rachel Lefebvre

Health By Bob Tedeschi

For cancer patients, newest treatments force the ultimate decision, with no room for error

Mick Phillips

Health By Rob Waters

Facing bleak odds, cancer patients chase one last chance — in Cuba

Elderly Immunotherapy

First Opinion By Ankur Parikh

We need more answers about immunotherapy for the elderly

ASH19 CAR-T and cancer cell

Biotech By Meghana Keshavan

Experimental cancer therapy holds great promise — but at great cost

T-Cells and cancer

Biotech By Sharon Begley

Beware the hype: Top scientists cautious about fighting cancer with immunotherapy

Immunotherapy scans

First Opinion By Raymond J. Tesi

Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay

Siddhartha Mukherjee

Business By Damian Garde

Pulitzer Prize-winning doctor wades into biotech with cancer startup

T-Cells and cancer

Biotech By Damian Garde

After a deadly clinical trial, will immune therapies for cancer be a bust?

All Coverage

Healthy human T cell

Politics By Casey Ross

Medicare proposes a boost in payments for CAR-T and other breakthrough drugs and devices

Breast Cancer Cell NCI National Cancer Institute

Health By Sharon Begley

Roche scores first U.S. approval of immunotherapy for breast cancer

advertisement

First Opinion By Neil Canavan

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds

Assasin within First Opinion illustration

First Opinion By Doreen Carvajal

Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope

Killer T cells surround a cancer cell

Adam's Take By Adam Feuerstein

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

Health By Associated Press

In a milestone year, gene therapy is finding a place in medicine

Colontown

Health By David Steen Martin

‘Colontown’ gives cancer patients an edge in finding new treatments

T-Cells and cancer

Lab Chat By Megan Thielking

Insight into exhausted immune cells could open new doors for cancer therapy

Human T lymphocyte

Biotech By Damian Garde

Separating hope from hype in the latest cancer treatment ‘revolution’

ASH19 CAR-T and cancer cell

Biotech By Damian Garde

Novel cancer treatment from Kite Pharma notches positive results, but big questions remain

Car-T challenges

Biotech By Meghana Keshavan

Hurdles abound in race to bring customized cancer treatments to masses

Paul Mihocko

In the Lab By Sharon Begley

In cancer, it’s back to the future as old treatments make cutting-edge ones more effective

Stephen Estrada

Health By Rebecca Robbins

For cancer patients on experimental immunotherapy drugs, it’s been an emotional week

Hans Bishop

Biotech By Damian Garde

FDA lets cancer trial resume after three patient deaths

Dendreon Corporation

Biotech By Sharon Begley

In Juno patient deaths, echoes seen of earlier failed company

FDA

Biotech By Damian Garde and Meghana Keshavan

Juno halts its immunotherapy trial for cancer after three patient deaths

Sean Parker & Craig Venter

Business By Sharon Begley

Sean Parker’s put up big bucks for cancer. We’ve got questions

Biden - Cancer moonshot

Politics By Dylan Scott

As Johns Hopkins launches new cancer center, Biden sees a model for his ‘moonshot’

Ebola virus - purple and green

Quick Take By Megan Thielking

These antibodies could protect against Ebola’s harms, but results come with a caveat

Patrick Soon-Shiong

In the Lab By Rebecca Robbins and Sharon Begley

Rival drug firms team up to test new approach to cancer treatment